Spyre Therapeutics, Inc. SYRE Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s unrealized gains on investments?
- Spyre Therapeutics, Inc. (SYRE) reported unrealized gains on investments of $290K in Q1 2026.
- How has Spyre Therapeutics, Inc.'s unrealized gains on investments changed year-over-year?
- Spyre Therapeutics, Inc.'s unrealized gains on investments decreased by 64.1% year-over-year, from $807K to $290K.
- What is the long-term trend for Spyre Therapeutics, Inc.'s unrealized gains on investments?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s unrealized gains on investments has grown at a 690.0% compound annual growth rate (CAGR), from $2K to $986K.